US Stock MarketDetailed Quotes

NVO Novo-Nordisk A/S

Watchlist
  • 77.870
  • -0.960-1.22%
Close Feb 14 16:00 ET
  • 78.300
  • +0.430+0.55%
Post 19:59 ET
345.79BMarket Cap24.53P/E (TTM)

About Novo-Nordisk A/S Company

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsv?rd, Denmark.

Company Profile

SymbolNVO
Company NameNovo-Nordisk A/S
Listing DateJul 9, 1981
Founded1931
CEOMr. Lars Fruergaard Jorgensen
MarketNYSE
Employees77349
Securities TypeDR
ADS Ratio1.0 : 1.0
Fiscal Year Ends12-31
AddressNovo Allé 1
CityBagsv?rd
ProvinceCapital Region
CountryDenmark
Zip Code2880
Phone45-44-44-88-88

Company Executives

  • Name
  • Position
  • Salary
  • Lars Fruergaard Jorgensen
  • Chief Executive Officer and President
  • --
  • Karsten Munk Knudsen
  • Executive Vice President and Chief Financial Officer
  • 26.40M
  • Marcus Schindler, PhD
  • Executive Vice President, Research and Early Development and Chief Scientific Officer
  • 23.60M
  • Maziar Mike Doustdar
  • Executive Vice President, International Operations
  • 2.20M
  • Ludovic Helfgott
  • Executive Vice President, Rare Disease
  • 2.20M
  • Camilla Sylvest
  • Executive Vice President, Commercial Strategy and Corporate Affairs
  • 23.40M
  • Henrik Ehlers Wulff
  • Executive Vice President, Product Supply, Quality Assurance, Digital Data and Information Technology
  • 25.90M
  • Martin Holst Lange
  • Executive Vice President, Development
  • 23.40M
  • Helge Lund
  • Chairman of the Board
  • 3.90M
  • Henrik Poulsen
  • Vice Chairman of the Board
  • 2.40M
  • Mette Bojer Jensen
  • Director
  • 1.30M
  • Liselotte Hyveled
  • Director
  • 1.10M
  • Elisabeth Dahl Christensen
  • Director
  • 1.10M
  • Thomas Rantzau
  • Director
  • 1.10M
  • Kasim Kutay
  • Director
  • 1.30M
  • Andreas Fibig
  • Independent Director
  • 1.40M
  • Christina Law
  • Independent Director
  • 1.70M
  • Dr. Sylvie Gregoire,Pharm.D.
  • Independent Director
  • 2.00M
  • Dr. Martin W. Mackay, PhD
  • Independent Director
  • 1.80M
  • Laurence Debroux
  • Independent Director
  • 2.10M
  • Tania Sabroe
  • Executive Vice President, People and Organisation
  • 2.20M
  • David Moore
  • Executive Vice President, US Operations and Business Development
  • 2.20M
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.